这些投资女神，今年带人赚翻了

Core Viewpoint - The article highlights the emergence of female fund managers in the pharmaceutical sector, particularly during the current innovative drug market boom, showcasing their impressive performance and unique investment strategies [3][6][18]. Group 1: Performance of Female Fund Managers - Zhang Wei, known as the "new pharmaceutical queen," leads the market with her fund, achieving a maximum return of 176.96% this year, with a current return of 142.74% as of October 13 [3][11]. - Other notable female fund managers, such as Ge Lan, Zhao Bei, and Tan Xiaobing, have also excelled, with their funds ranking high in performance, reflecting diverse investment philosophies in the innovative drug sector [5][18]. - The overall performance of these fund managers indicates a strong recovery in the innovative drug market after a prolonged downturn [7][18]. Group 2: Investment Strategies - Zhang Wei's investment strategy focuses on large-cap stocks in the pharmaceutical sector, with 90.83% of her portfolio allocated to pharmaceutical and biotechnology companies, reflecting a significant increase of 28.55% from the previous period [11][15]. - Ge Lan emphasizes cross-border collaborations and clinical expectations, actively participating in private placements to enhance risk-reward ratios [28][29]. - Zhao Bei adopts a more conservative approach, diversifying her portfolio to include both innovative and traditional pharmaceutical companies, aiming to balance risk and growth [31][32]. Group 3: Market Dynamics and Future Outlook - The article notes a significant divergence in the performance and scale of pharmaceutical funds, with some funds experiencing a decline in assets despite strong returns, indicating a shift in investor behavior [19][23]. - The innovative drug sector is expected to enter a growth phase, driven by supportive policies, increased international transactions, and a projected surge in revenue for innovative drug companies by 2025 [35][36][41]. - The article concludes that the current favorable conditions for innovative drugs will likely sustain for the next two to three years, providing a platform for fund managers to implement their diverse investment strategies [43][44].